phase 3_initiation
saveIncyte Corp — retifanlimab (Phase III Trial Initiation)
community read0 votes
Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma
Data sources
globaldata
Found something off?
drug timeline · 5
- approvalZYNYZ (RETIFANLIMAB-DLWR) — FDA approvalMar 30, 2026 · 194d ago
- approvalZYNYZ (RETIFANLIMAB-DLWR) — FDA approvalDec 17, 2025 · 297d ago
- approvalZYNYZ (RETIFANLIMAB-DLWR) — FDA approvalMay 15, 2025 · 513d ago
- approvalZYNYZ (RETIFANLIMAB-DLWR) — FDA approvalApr 22, 2024 · 901d ago
- approvalZYNYZ (RETIFANLIMAB-DLWR) — FDA approvalMar 22, 2023 · 1298d ago
comments(0)
5-min edit window · permanent after that